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ABSTRACT
Objectives Treatments for prostate cancer such
as androgen deprivation therapy (ADT), surgery
and radiation therapy can adversely affect sexual,
urinary and bowel function. Preliminary research
has demonstrated the efficacy of exercise to
preserve sexual function in men with localised
prostate cancer receiving ADT, though this has
yet to be investigated in a metastatic setting.
We examined the effects of a 12-week exercise
programme comprising resistance, aerobic and
flexibility training on sexual health and function
in men with advanced prostate cancer.
Methods Patients with prostate cancer
(70.0±8.4 year; body mass index 28.7±4.0 kg/
m2) with bone metastases (rib/thoracic spine,
66.7%; lumbar spine, 43.9%; pelvis, 75.4%;
femur, 40.4%; humerus, 24.6%; other sites,
70.2%) were randomly assigned to supervised
exercise 3 days/week (n=28) or usual care
(n=29). Sexual health and function were
assessed using the International Index of Erectile
Function, the Expanded Prostate Cancer Index
Composite and the EORTC-PR25 at baseline and
12 weeks.
Results Patients attended 89% of planned
sessions and there were no adverse events.
After adjusting for baseline values, there was no
significant difference between groups for any
measure of sexual function and activity (p>0.05).
Additionally, there was no significant difference
between groups for urinary and bowel function
assessed by the EORTC-PR25 (p>0.05).
Conclusions A short-term programme of
supervised exercise does not appear to enhance
indices of sexual health and function in men
with advanced prostate cancer. Limitations of the
intervention included the conservative modular
exercise programme, which deliberately avoided
loading bone metastatic sites.
Trial registration
number ACTRN12611001158954.

BACKGROUND
Treatments for prostate cancer (PCa)
such as androgen deprivation therapy
(ADT), surgery and radiation therapy
can adversely affect sexual, urinary and
bowel function that may persist for years
following cessation of treatment. The
psychosexual burden on individuals with
PCa is complex, impacted by the physical
result of erectile dysfunction, in addition
to the psychosocial impact of reduced
sexual function, including shame, depression, loss of intimacy and so on.1 Prior
research supports the use of exercise as
an effective countermeasure to many of
the treatment-
related toxicities experienced in men with PCa, though research
in regards to exercise and sexual function
in this area remains sparse. Nevertheless,
higher levels of physical activity have been
demonstrated to be significantly associated with better sexual functioning in men
with PCa following radiotherapy.2 Moreover, our group has previously demonstrated the ability of exercise to preserve
sexual function in men with localised and
locally advanced PCa receiving ADT.3
However, the effects of exercise on sexual
function in men with PCa in a metastatic
setting have yet to be investigated.
We recently reported the findings from
an exercise trial undertaken in patients
with PCa with bone metastases in which
self-
reported improvements in physical
function and objectively measured lower
body strength resulted.4 Here we report
the effects of the 3-
month multimodal
exercise programme on sexual activity in
this same patient cohort.
METHODS
Participants and recruitment

As previously reported,4 103 patients
with PCa with established bone metastases were referred by their oncologist
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or urologist to participate, with 57 patients enrolled
in the trial. Individuals were excluded if they had any
conditions that precluded safe exercise, or if patients
were currently participating in structured exercise.
The main reasons for exclusion were patients declined
to participate (n=16), travel constraints/proximity to
exercise site (n=9), other commitments (n=6), physician declined approval (n=5) and bone pain (n=5).
Informed consent was obtained from all participants
and the study was approved by the University Human
Research Ethics Committee.
Study design and random assignment

This was a two-
armed prospective randomised
controlled trial.4 Assessments of body composition
(dual-energy X-ray absorptiometry), physical function,
psychosocial measures and blood biomarkers were
obtained at baseline and after the 12-week intervention. Following baseline assessments, patients were
randomised in a ratio of 1:1 to either exercise or usual
care using a computer-generated random assignment
programme.
Exercise training programme

Details of the exercise programme have been described
in detail elsewhere.4 Briefly, the programme was
undertaken three times per week in an exercise clinic
for ~60 min, supervised and comprised resistance,
aerobic and flexibility exercise, using a modular
approach with extent/location of bone metastases
taken into account to avoid loading of the affected
sites. Resistance exercise targeted major upper and
lower body muscle groups involved three sets at 10–12
repetition maximum intensity, using exercises (such as
chest press, seated row, triceps extension, biceps curl,
leg extension and leg curl) tailored to the individual in
relation to metastases sites. Aerobic exercise involved
20–30 min at 60%–85% estimated maximal heart rate
using modes such as walking and cycling, while flexibility training involved static stretching of the major
muscle groups.
Outcomes

Outcome measures were erectile function using the
International Index of Erectile Function (IIEF),5
urinary, sexual, bowel and hormonal health-
related
quality of life domains using the Expanded Prostate
Cancer Index Composite (EPIC)6 and disease-specific
health-related quality of life using the EORTC-PR25.7
Higher scores on the IIEF and EPIC questionnaires
indicate higher levels of sexual, urinary and bowel
function and sexual activity. For the EORTC-PR25,
higher scores on the urinary, bowel and treatment
symptom scales indicate higher symptomology/problems while a higher score for sexual activity indicates a
higher level of functioning.
Statistical analyses

Data were analysed using IBM SPSS (IBM, Armonk,
New York, USA). Normality of the distribution was
2

determined using the Shapiro-
Wilk test. Between-
group differences in baseline characteristics were analysed using independent t-tests or the Mann-Whitney U
test for continuous data, as appropriate, and χ2 test for
categorical data. Analysis of covariance adjusted for
baseline values was used to assess intervention effects
on study outcomes. Data for the three outcome questionnaires (IEEF, EPIC and EORTC-PR25) were not
normally distributed, consequently all outcome data
were log transformed for analysis. Due to incomplete
responses to some of the questionnaires, analysis was
conducted using complete cases. Tests were two-tailed
with significance set at an alpha level of p ≤0.05.
RESULTS
The men were aged 50–89 years with extensive bone
metastatic lesions. There were no significant differences between groups at baseline for patient characteristics (online supplemental table S1 in online
supplemental file) and sexual activity and function
(table 1), except for the EPIC, which was significantly
higher (p=0.004) in the exercise group (table 1). No
exercise-
related adverse events or skeletal fractures
were reported during the study and patients attended
89% of planned sessions. After adjusting for baseline
values, there were no significant differences for any
measure of sexual function and activity following
exercise (table 1). Additionally, there were no significant differences for any measures of urinary and bowel
function. When examining individual responsiveness
to exercise, no patterns emerged for the outcome
measures.
DISCUSSION
This is the first study reporting the effects of exercise
on sexual activity and function in men with advanced
PCa. The findings from our trial indicate that although
patients with advanced PCa and bone metastases were
able to undertake the exercise programme with no
adverse events reported, it had no effect on indices
of sexual function. A lack of effect of exercise in the
current study may be due to the short-term nature of
the exercise programme being only 3 months and the
conservative modular exercise programme avoiding
bone metastatic sites, providing an insufficient stimulus to induce change in sexual function or activity.
For many patients, this conservative exercise prescription precluded compound resistance training exercises
involving the large muscle groups. This likely limited
neural, muscular, hormonal and systemic training
adaptations potentially mechanistic in improving
sexual function and activity. It is also possible that
exercise alone may be insufficient to produce favourable changes in sexual function and activity in men
with advanced disease compared with those with localised disease.3
Currently, there is insufficient evidence regarding
which interventions are effective in helping to manage
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Table 1

Effects of exercise on sexual activity and function
Baseline

Measure

Exercise

3 months
Control

Exercise

Adjusted change
Control

Mean (95% CI)

P
value*

IIEF
Erectile functioning (n=17 to 20)
3.4 (7.2)
2.7 (5.1)
3.7 (7.2)
3.8 (6.2)
−1.0 (−3.7 to 1.8)
0.484
Orgasmic functioning (n=17 to 20)
2.0 (1.8)
2.1 (1.6)
0.5 (1.2)
1.3 (2.8)
−0.6 (−1.9 to 0.7)
0.349
Sexual desire (n=16 to 20)
3.4 (2.1)
3.5 (1.9)
3.2 (2.4)
3.2 (1.7)
0.2 (− 0.7 to 1.1)
0.644
Intercourse satisfaction (n=17 to 20)
0.9 (2.9)
1.0 (2.6)
1.6 (3.5)
1.5 (2.6)
0.1 (−1.4 to 1.6)
0.893
Overall satisfaction (n=15 to 20)
4.4 (2.8)
4.3 (3.2)
4.8 (2.8)
3.8 (2.4)
1.3 (−0.4 to 2.9)
0.122
EPIC
24.2 (15.0)
18.3 (19.3)
−4.1 (−12.2 to 3.9)
0.304
Sexual summary (n=18 to 23)
28.8 (16.6)
15.9 (14.9)†
EORTC QLQ-PR25
Sexual activity (n=19 to 26)
22.2 (27.3)
20.1 (19.6)
23.7 (23.7)
15.4 (19.9)
4.3 (−7.2 to 15.9)
0.455
Urinary symptoms (n=20 to 25)
16.2 (16.1)
20.1 (17.5)
13.9 (11.9)
22.0 (14.3)
−3.7 (−8.7 to 1.2)
0.079
Bowel symptoms (n=18 to 25)
4.4 (7.1)
6.3 (9.8)
6.9 (8.6)
6.0 (9.4)
1.4 (−3.7 to 6.5)
0.585
Treatment symptoms (n=19 to 26)
13.5 (14.8)
17.7 (15.3)
16.9 (13.0)
21.7 (14.2)
−3.2 (−10.4 to 4.1)
0.384
Values are the mean (SD), and adjusted change and 95% CI are from untransformed data. Numbers in parentheses represent the number of exercise and
control patients.
*Baseline differences were assessed using the Mann-Whitney U test and intervention effects using ANCOVA with p values derived from log-transformed
data.
†Statistically significant difference at baseline.
ANCOVA, Analysis of Covariance; EORTC QLQ-PR25, The European Organisation for Research and Treatment of Cancer prostate cancer-specific module;
EPIC, Expanded Prostate Cancer Index Composite; IIEF, International Index of Erectile Function.

sexual dysfunction in PCa. Sexual function and sexual
satisfaction though interrelated are distinct entities
that are likely impacted by the complex interplay
between natural ageing, treatment-related factors and
psychosocial or interpersonal variables such as coping
and intimacy. Emerging evidence suggests that psychological therapies may be effective in improving sexual
health in PCa.8 It is likely that exercise may play a role
in a larger, multimodal framework (including psychosexual therapy, couples support, pharmacology etc.),
rather than as a stand-
alone intervention. Further,
given the extensive benefits experienced by men with
PCa undertaking exercise, including enhanced muscle
mass, strength, physical function and quality of life,
future research empirically testing an integrative
model of PCa care may look to include exercise as a
core component. In addition, the inclusion of targeted
pelvic floor exercise as part of the overall programme
might also be beneficial for this patient group, especially for those with extensive bone disease and unable
to perform multiple resistance exercises and could be
considered in future studies. In summary, although
exercise was well tolerated and improved physical
function, the results of our trial suggest that a short-
term stand-
alone exercise programme has no effect
on indices of sexual health in men with advanced PCa
with bone metastases.
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